Abstract
Background The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 to 35 months, as reported in seven randomized clinical trials (RCTs). In addition, latest results of RCTs show significantly different outcomes for patients with exon 19 deletion and L858R mutation. To find out whether efficacy of EGFR TKIs is comparable in routine clinical practice, the overall survival (mOS) analysis of consecutive advanced EGFR-mutated patients routinely treated with EGFR TKIs from January 2010 to December 2013 in one academic institution was performed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
